Biotech Valuation Message Board

We're offering Lifetime and discounted 3-year Subscriptions this month only. Details here

Message Boards | Biotechnology : Biotech Valuation -- Ignore and Intra-subject Search unavailable to you. Want to Upgrade?

Posts: 32992 | Member SubjectMarks: 636 | Bans (1) | Board Shortcut:

Moderated By: Biomaven -- (Moderated) -- Started: 2/24/1999 11:45:00 AM Revision History

Go to reply# or date (mm/dd/yy):

Reply	Subject	From	Recs	Date
32992	A relatively positive and informative article on the Senate bill: http://poli	Biomaven	-	11/24/2009 12:55:12 PM
32991	Here's some background on so-called "foreign-cubed" litigation: http://www.la	Biomaven	-	11/24/2009 11:30:52 AM
32990	Another high horse post from me here. Just read	Robohogs	2	11/24/2009 09:14:55 AM
32989	LOL, John. But, yes, there is a lot of mysticism / spirituality in the biotec	FiloF	-	11/24/2009 09:06:51 AM
32988	Peter, if it weren't you who contributed this article, I would have thought it w	John Metcalf	1	11/23/2009 10:49:25 PM
32987	I certainly think that Mon is less risky than any other Biotech I own. I was fe	A.J. Mullen	-	11/23/2009 10:26:48 PM
32986	Well maybe Medicare still won't pay for anti-rejection drugs, but I guess coveri	Biomaven	1	11/23/2009 09:51:58 PM
32985	>>parse that sentence a second time before I realized that TAU referred to the u	Biomaven	-	11/23/2009 09:40:22 PM
32984	Thanks for that post—I think MON will be a standout stock over the next 5-10 yea	DewDiligence_on_SI	-	11/23/2009 08:27:14 PM
32983	<i>>TAU finds that a destructive protein is also essential for normal brain func	DewDiligence_on_SI	-	11/23/2009 08:22:28 PM
32982	ARCA in-licensed this drug from Indevus and another company in 2003. The develop	DewDiligence_on_SI	-	11/23/2009 08:18:15 PM

Go to reply# or date (mm/dd/yy):

You are on WEB1.